MARC details
| 000 -CABECERA |
| campo de control de longitud fija |
05039nam a22003255i 4500 |
| 001 - NÚMERO DE CONTROL |
| campo de control |
402807 |
| 003 - IDENTIFICADOR DEL NÚMERO DE CONTROL |
| campo de control |
ES-MaUEC |
| 005 - FECHA Y HORA DE LA ÚLTIMA TRANSACCIÓN |
| campo de control |
20240708130802.0 |
| 006 - CÓDIGOS DE INFORMACIÓN DE LONGITUD FIJA--CARACTERÍSTICAS DEL MATERIAL ADICIONAL |
| campo de control de longitud fija |
a||||fo|||| 00| 0 |
| 007 - CAMPO FIJO DE DESCRIPCIÓN FÍSICA--INFORMACIÓN GENERAL |
| campo de control de longitud fija |
cr nn 008mamaa |
| 008 - DATOS DE LONGITUD FIJA--INFORMACIÓN GENERAL |
| campo de control de longitud fija |
231114s2023 si | fo |||| 0|eng d |
| 020 ## - NÚMERO INTERNACIONAL ESTÁNDAR DEL LIBRO |
| Número Internacional Estándar del Libro |
9789819961634 |
| 024 7# - IDENTIFICADOR DE OTROS ESTÁNDARES |
| Número estándar o código |
10.1007/978-981-99-6163-4 |
| Fuente del número o código |
doi |
| 040 ## - FUENTE DE LA CATALOGACIÓN |
| Centro catalogador/agencia de origen |
ES-MaUEC |
| Lengua de catalogación |
spa |
| Centro/agencia transcriptor |
ES-MaUEC |
| Centro/agencia modificador |
ES-MaUEC |
| 050 #4 - SIGNATURA TOPOGRÁFICA DE LA BIBLIOTECA DEL CONGRESO |
| Número de clasificación |
R853.H8 |
| Número de documento/Ítem |
2023 EB |
| 245 00 - MENCIÓN DE TÍTULO |
| Título |
Ethical Innovation for Global Health : |
| Resto del título |
Pandemic, Democracy and Ethics in Research |
| Mención de responsabilidad, etc. |
edited by Chieko Kurihara, Dirceu Greco, Ames Dhai |
| 250 ## - MENCIÓN DE EDICIÓN |
| Mención de edición |
1st ed. 2023 |
| 264 #1 - PRODUCCIÓN, PUBLICACIÓN, DISTRIBUCIÓN, FABRICACIÓN Y COPYRIGHT |
| Producción, publicación, distribución, fabricación y copyright |
Singapore |
| Nombre del de productor, editor, distribuidor, fabricante |
Springer International Publishing |
| Fecha de producción, publicación, distribución, fabricación o copyright |
2023 |
| 300 ## - DESCRIPCIÓN FÍSICA |
| Extensión |
1 recurso en línea |
| 336 ## - TIPO DE CONTENIDO |
| Término de tipo de contenido |
texto |
| Código de tipo de contenido |
txt |
| Fuente |
rdacontent |
| 337 ## - TIPO DE MEDIO |
| Nombre/término del tipo de medio |
electrónico |
| Código del tipo de medio |
c |
| Fuente |
rdamedia |
| 338 ## - TIPO DE SOPORTE |
| Nombre/término del tipo de soporte |
recurso electrónico |
| Código del tipo de soporte |
cr |
| Fuente |
rdacarrier |
| 505 0# - NOTA DE CONTENIDO CON FORMATO |
| Nota de contenido con formato |
1 Introduction to Ethical innovation for global health: pandemic, democracy and ethics in research. Part 1 Relevant constructions from a middle-income country (MIC) and/or non-Western paradigms: Brazil, South Africa, Taiwan, South Korea, and Japan -- 2 Democracy restoration in Brazil, the constitutional guarantee of health as a right for all, giving rise to a universal health system (SUS) and of a National Research Ethics Commission -- 3 Equitable access to COVID-19 vaccines, vaccine research and Vaccine Apartheid on the African continent: challenges and recommendations -- 4 Response to Covid-19 pandemic and Ethical Innovations in Taiwan -- 5 Between truth and profit: Scientific misconduct case of human cloned embryonic stem cell and revisiting cases during COVID-19 pandemic -- 6 Therapeutic misconception as the basis for vaccine nationalism of Japan: a historical reflection and perspectives for global public health -- Part 2 Historical and international perspectives on the development of ethical principles in research involving humans -- 7 The Declaration of Helsinki as a living document: Revisiting its principles in a global pandemic -- 8 Hidden Medical War Crimes and the Emergence of Bioethics in Japan -- 9 From Nuremberg to Helsinki: Historicizing the Codification of Post-War Research Ethics -- 10 CIOMS research guidelines: Considering the needs of developing countries -- 11 Ethics of placebo-controlled trial: historical analysis including the experience of COVID-19 pandemic -- 12 Post-trial access: historical analysis considering the experience of COVID-19 pandemic -- 13 Our "WMA Declaration of Helsinki": opinions and pro-posals from patient and public for research ethics -- Part 3 Alternative frameworks for innovation and drug development strategies -- 14 Medicines development for global health: Learning from COVID-19 vaccines R&D -- 15 Development of portfolios and pipelines of drugs for the treatment, prevention and control of neglected tropicaldiseases -- 16 Patient and Public Involvement (PPI) and pharmaceutical development through Open Innovation Processes ~ recent activities. |
| 520 ## - SUMARIO, ETC. |
| Sumario, etc. |
This volume captures the recent changes and evolution in ethics in research involving humans and provides future directions to achieve alternative drug development strategies for equitable global health. It presents ethical considerations in current day clinical trials and new trends of ethics in research. It also describes the historical context, illustrates the process in alternative paradigms to achieve democracy after World War II, how the framework of ethics in research was established in different regions, and policies implemented to protect research participants from the exploitation of new drug development. The book is organized into three themed parts: relevant constructions from Brazil, South Africa, Taiwan, South Korea, and Japan; historical and international perspectives of principles of ethics in research; and alternative frameworks of clinical development and innovation. Ethical Innovation for Global Health: Pandemic, Democracy and Ethics in Research is an informative resource for academic researchers, the global pharmaceutical industry, regulators, civil society and other role players involved in global health. It is contributed to by leaders in global policy development in research ethics, and experts in drug development activities with its trajectory being global health. The COVID-19 pandemic, as a global disaster, necessitated not only socio-economic but also cultural transformation. While effective vaccines were developed under a successful new methodology, there remains inequity of distribution of these vaccines globally. The book re-engages with the notion of the primacy of distributing results of scientific innovation to those who most require the benefits. |
| 988 ## - NOTA LOCAL 598 |
| Nota local 598 (boletines) |
Springer_Medicine_2023 |
| 650 #7 - PUNTO DE ACCESO ADICIONAL DE MATERIA--TÉRMINO DE MATERIA |
| Fuente del encabezamiento o término |
embne |
| 9 (RLIN) |
674241 |
| Término de materia o nombre geográfico como elemento de entrada |
Experimentación humana en medicina |
| 856 40 - LOCALIZACIÓN Y ACCESO ELECTRÓNICOS |
| Identificador Uniforme del Recurso |
https://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-981-99-6163-4 |
| Nota pública |
Acceso a este recurso digital (usuarios Universidad Europea de Madrid) |
| 942 ## - ELEMENTOS DE PUNTO DE ACCESO ADICIONAL (KOHA) |
| Fuente del sistema de clasificación o colocación |
Library of Congress Classification |
| Tipo de ítem Koha |
LIBRO-E NO PRÉSTAMO |
| 998 ## - DATOS ESTADÍSTICOS |
| Fecha de catalogación |
07/2024 |
| Tipo de materia |
E-book |
| Catalogador |
Ana Nieves |
| Catalogado |
Sí |